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Abstract
Feline Leukemia Virus (FeLV) is a transmittable RNA retrovirus that inhibits feline
immune systems and predisposes its host to infections and diseases. Much is unknown about
FeLV, including the nature and location of its insertion sites. Identifying insertion sites of the
provirus can provide information about mechanisms of tumorigenesis and identifY new proto-
oncogenes. To search for insertion sites, gene-specific primers were designed and a genome
walking method was optimized for our application. Using the optimized process, blood and
tissue samples were examined for FeLV provirus. The cat from which we received samples
showed neurological symptoms before death; therefore, we hypothesized FeLV sequences would
be present in brain tissue. We also hypothesized that brain sequences and insertion sites would
differ from specific sequences found in blood and other tissue samples. Exogenous FeLV-B
sequences were successfully amplified from blood, brain and lymph tissues and no differences
were found between sequences. Exogenous sequences in the brain indicate the presence of
cellular receptors recognizable by FeLV-B. This is significant because previous research
suggested that brain cells have a resistance to the virus. Furthering knowledge of mechanisms
and locations of insertion can lead to a more complete understanding of FeLV disease
progression, ultimately leading to the development of more effective treatments, conserving the
health of domesticated and large endangered feline species.
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Introduction
Oven'iew
Feline Leukemia (FeLV) is a gamma retrovirus that integrates into host DNA, where
the virus remains for the lifespan of the host. The virus inhibits the immune system of various
feline species and predisposes its hosts to infections and diseases.f1J FeLV is particularly
threatening because of its symptoms and contagious nature. Transmitting the virus can occur
though contact with bodily fluids of an infected cat and therefore FeLV is a leading killer
among domesticated and wild cats. Reported recently, FeLV has infected large cat species
such as the Puma conc%r and the Lynx pardinus, posing a risk to endangered species and
demonstrating the possible vulnerability of all felines to the virus.[2J
Feline Leukemia Virus is separated into four subgroups (A, B, C, and T), each of
which uses different cellular receptors to enter the host and bring rise to different symptoms.
All infected felines carry FeLV-A, a horizontally transmissible and weakly pathogenic
subgroup.f3l FeLV-B and FcLV-C subgroups are only present when FeLV-A is present.
FeLV-B occurs in around half of infected cats, and is most often diagnosed in hosts that have
developed tumors. FeLV-C is less common, occuring in approximately 5% of FeLV-positive
cats, and is associated with acute anemia. FeLVeT is the most rare subgroup, accounting for
<1% FeLV cases. It has been linked with immune suppression similar to feline
immunodeficiency virus. Currently, there are no effective treatments for any subtype of
FeLV.
Mechanisms of pathogenesis are not fully understood; however, studies of FeLV-host
interactions have been used to develop theories for FeLV insertion mechanisms. Current
I
2theory suggests that FeLV inserts randomly into the feline DNA.!4} However, studies of
FeLV-induced tumors have identified sites into which FeLV has inserted more often than
would be predicted statistically, including proto-oncogenes -c-myc, pim-l andjlvi-2.f5J Our
research has focused on developing a reliable and repeatable method to search for integration
sites and gaining more information about the host genetic sequences into which each strain of
FeLV integrates.
FeL V Structure
The Feline Leukemia virus is a spherical gammaretrovirus with an envelope and a
reported diameter of approximately 110 millimicrons. The structure and viral components,
including surface proteins, integrase, matrix, capsid, viral RNA genome, and reverse
transcriptase, of FeLV are depicted in Figure I. The membrane surrounds the capsid and has
protruding glycoproteins, biologically active dimers. Glycoproteins are surface proteins that
facilitate entry into a host cell because they have transmembrane subunits that bind to a
receptor and C-tenninal region, allowing fusion between the virus and cell membrane.!6}
Under the surface proteins is a matrix that houses a capsid. The capsid is a protein shell that
surrounds its genetic materia!. Enclosed within the capsid are viral enzymes, viral proteases,
reverse transcriptase, and integration proteins. Integrase is a specific viral enzyme that is
produced by retroviruses and enables genetic material to be integrated into host DNA.f7J
Surface
Proteins
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Figure 1: Structure of FeLV. This illustration contains viral components described above as
well as a single stranded RNA depicting the viral RNA Genome.
After the virus enters the cell, viral reverse transcriptase make DNA copies of the
RNA genome. In the nucleus, integrase inserts proviral DNA into the host genomic DNA
where it can then be transcribed, producing mRNA. mRNA allows the translation of viral
proteins and RNA for new virions. Budding and cleavage then occurs in the cell
membrane.f8J
The FeLV genome is made up of three genes- the gag gene, pol gene, and env gene-
which code for nine viral proteins. The gag gene codes for four internal structural proteins
that connect the retrovirus to the envelope, form primary structural proteins for the virus'
core, and form nucleocapsid proteins. The pol gene codes for three viral enzyme proteins that
allow synthesis of DNA from single stranded RNA templates and integration of viral DNA
provirus into the host genome. Lastly, the env gene codes for two glycoproteins that identify
4pol
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the viral subgroup/9] The proviral DNA is illustrated below:
promoter and enhancer clements
Figure 2: Proviral DNA. The structure of the integrated FeLV provirus, including the
viral genes (gag, pol, env) and the long terminal repeat (LTR). Natural isolates of FeLV show
great variation in the LTR, often with a duplicate enhancer or other repeat sequences. Specific
LTR variants have been linked to different disease progression and outcome, though the
mechanisms are not fully understood.
Prevalence in Nature
FeLV is an increasing issue in nature because the virus is highly contagious.
Transmission occurs though contact with bodily fluids of an infected cat including saliva,
mucus, urine, feces, milk, and blood. Merely a scratch ora shared litter box can facilitate the
transmission of the virus. Viremia often sets in very quickly. The short time period between
infection and onset of symptoms makes containment of the virus very difficult. Infection can
also result in the host having a latent period where it is infected but does not experience
symptoms. A cat can test negative during a latent period and therefore would not be
perceived as a threat. In this situation, the infected cat is often integrated into a home. This
leads to transmission because the feline still has potential to spread the virus after the latent
periodJiO] For this reason, many veterinarians suggest that a cat be tested twice for FeLV, the
first test should be administered immediately and the second test should be used to verify
sixty days later. It is important to note that very rarely infected felines can clear the virus to
an undetectable point and therefore never transmit the virus. In this case, the cats are not
viremic, but do have proviral DNA. Still, research shows that these cats are more susceptible
to illness for unknown reasons/II]
FeLV is a vims that has been found in felines all around the world. Prevalence of the
infection varies depending on environment, access to vaccinations, age, and lifestyle. While
approximately 3% of cats in the United States have been found infected, the amount of
infected kittens is more than 13%, and the amount of infected wild cats is thought to be over
40%. Not all cats are tested so estimating the statistical prevalence of FeLV is challenging.
Researchers estimate that as much as 15% of the feline population carries FeLV. Still the
most grisly fact is that FeLV is always fata!.!l2]
A large concern in the field of research for FeLV came when cases of infection were
found in the Florida panther, one of the most endangered feline and animal on earth.
Researches do not know how the disease was introduced to the large, wild feline species;
however, preservation efforts were strong and vaccines were administered to as many Florida
panthers as possible.[3] This outbreak demonstrates the potential danger of the disease to all
feline species and should bring about urgency in research.
FeL V Subtypes
Feline Leukemia Vims is separated into four subtypes- FeLV-A, FeLV-8, FeLV-C,
and FeLV-T. Each subtype uses different cellular receptors to enter the host and bring rise to
different symptoms summarized in Table I. All felines infected with the virus can'y subtype
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6A. Both FeL V -B and FeL V-C are thought to arise from recombination of FeL V-A with
endogenous viral sequences and mutation. The four subtypes have been shown to have
differing glycoprotein sequences in the envelope, resulting in different pathogenesis/13J For
example, FeL V -Tis the only subtype to require the virus to bind to the receptor as a
prerequisite for transaetivation. Of the four subtypes, FeLV-A is the only one horizontally
transmitted.
It is important to note that a small percent of infected felines develop a non-productive
infection and carry the integrated provirus without the presence of the virus in the blood.
However, they are still infected, and viral production can activate in times of duress.f!4J
Table 1: FeLV Subtypes. The symptoms, origin, and characteristics of PeL V subtypes are
compared to clarify differences between subtypes and to enhance understanding.
Subtype Symptoms Origin Characteristics
FeLV-A Hematopoietic Original FeL V strand; -Pathogenic
neoplasia, all infected cats carry -Causes structural changes in host
-Highly contagious
-Present in all infected feline
-Affects tissuesin the liver, kidney,
small intestines, and T cells
-Uses thiamine transport protein
receptor for entry
FeLV-B Typically Polytropic virus found -Non-pathogenic by itself
asymptomatic in conjuction with -Pathogenic when recombined with
FeLV-A; arises by FeLV-A
recombination of FeL V- -Uses Pit I and Pit2 receptors for cell
A with endogenous entry
retroviral sequences
FeLV-C Anemia, Polytropic virus found -Does not replicate
erythremic in conjuction with -Non-contagious
myelosis FeL V-A; arises by -A ffects stem cells that give rise to red
(leukemia) mutation of env genes blood cells
fromFeL V-A subgroup -Uses heme exporting protein receptor
FeLV-T Lymphopenia, Evolved from mutation - Only subtype to require the virus to
neutropenia, and recombination of bind to the receptor as a prerequisite for
fever, diarrhea FeLV-A transactivation
-Affects T-cells
-Uses Pit I and co-receptor feLIX for
cell entry
Genome Walking with Polymerase Chain Reaction
Genome walking is a biological method used to determine unknown DNA sequences
that lie adjacent to known sequences. This efficient and reliable method uses Polymerase
Chain Reaction (PCR). PCR is an effective biological technique for selectively amplifying
specific DNA segments, resulting in anywhere from thousands to millions of copies of that
DNA sequence. The technique has a few components including a DNA template, DNA
polymerase, primers, and nucleotides. The DNA template is the piece of DNA that contains
the target sequence. DNA polymerase is an enzyme that synthesizes new strands of DNA
complementary to the target sequence. Lastly, primers are short, single-stranded DNA pieces
that are complementary to the target sequence and allow polymerase to begin synthesis.
PCR begins by heating a sample to denature DNA. The DNA is separated to two
single-stranded pieces of DNA. DNA polymerase then uses these original strands as
templates to synthesize two new stands of DNA. The two newly synthesized copies are then
used to create two new copies. This cycle, of denaturing and duplicating, repeats itself
resulting in numerous copies of the sample DNA. These PCR processes are automated and
take place in a thermocycler that can be programmed to varying conditions. Figure 3 gives
you a visual illustration ofPCR amplification:
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Figure 3: PCR Amplification. (a) This section depicts the first PCR cycle. The
double-stranded DNA template is illustrated with primers represented by the blue and red
pieces. Primers anneal, the original DNA strand denatures, and new strands are synthesized.
Green segments represent new strands of DNA. (b) This section depicts the second PCR cycle
in which the process shown in section (a) is repeated. (c) This section shows the
accumulation of the target product. Two copies of the template DNA are produced per cycle,
leading to exponential growth.
Touchdown PCR (TD-PCR) is a variation ofPCR that uses a higher annealing
temperature, the upper limit of the primer's melting point. This results in specific base paring
of primer to template. It is used to increase specificity of amplification by avoiding
nonspecific primer binding in the first few cycles with high annealing temperatures.
Temperature is gradually lowered throughout the cycling process. Nonspecific primer
binding is an issue because unwanted sequences can interfere with efficient amplification of
sequences of interest. By lowering the annealing temperature of the cycling process
progressively, the target sequence is selectively amplified at the beginning, avoiding
significant amplification of unwanted sequences.
Materials and Methods
DNA
Blood and various tissue samples were donated by a local veterinarian who works for
a FeLV shelter, Leuk's Landing Leukemia Rescue for FeLV-positive cat samples. Blood
samples from two cats, labeled cat 8 and 23, were used. Tissue samples included brain, liver,
spleen, kidney, and mesentery lymph samples. These samples were provided from cat 23.
Primers
Primers for PCR amplification were designed using the National Center for
Biotechnology Information's Primer-BLAST tool. The primers were designed to be specific
for the template of interest and were cross checked using the nucleotide database. The first
set of primers used to confirm the presence of FeLV-B was RB53 and RB I7. RB53 is a
forward primer and RB 17 is a reverse primer:
RB53 (F) ACAACGGGAGCT AGTG
RBI7(R) TAGTGATATTGGTTCTCTTCG
9
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Since optimal annealing temperature for Touchdown-PCR is based on melting
temperatures of the primer-template pair and Gibbs free energy of oligonucleotides effects
optimization of conditions, Table 2 helps understand the optimization ofTD-PCR conditions.
Table 2: Melting temperatures and maximum ,iG. The table lists melting temperatures
and maximum ,iG values for each primer used. Calculations were performed using IDT
OligoCa!c, with 0.25 11Meach primer, 50 mM Na+, and 1 mM dNTPs.
Tm (DC) ,iG (kcal/mol)
BWF:CTAGTGAAGGGGGCCGGTGCAACCC 68.8 -55.55
BWR:CGGGACCTGGCAGTTTTGTCGAAGTGT 66.8 -54.46
BIF:CCCCCATCCTGCCTATCTATTCCGCA 65.8 -55.05
B2F:GCCTTAAATGCCACCGACCCCAACAA 65.9 -55.48
B3F: TCCCCCATCCTGCCTATCTATTCCGC 65.6 -54.67
B5F:TCCCGAGTAACACCTCACCATTCCCA 65.3 -51.03
BIR:GGTCCAATTGAGCACCGCCATGGAAA 65.9 -54.74
B2R:TGCGGAATAGATAGGCAGGATGGGGG 65.8 -55.05
B3R:CGGCTAGATAGTGCGCCCCTGTATGT 65.8 -52.61
B5R:AGCCTGGTGGGTCTTAGGAACAGTCC 65.7 -50.35
The primers used can be visually represented on the proviral envelope shown in Figure 4:
~
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Figure 4: Primer Information. Displays the four forward (blue) and four reverse
(red) primer positions and orientations between 13-1411 base pairs (on the template). These
primers were designed with high melting for use with a touchdown peR protocol to help
improve amplification of FeLV sequences.
DNA Extraction
Blood Samples
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Extraction of DNA from blood samples was performed using PureLink@ Viral
RNA/DNA Purification Kit from Life Technologies. Life Technologies' protocol
was followed and the samples were stored at -80°C
Tissue Samples
Extraction of DNA from tissue samples was performed using a Nucleospin
Tissue Genomic DNA Extraction Kit from Clontech. Clontech's protocol was
followed and samples were stored at -80°C.
DNA Digestion
The use of restriction enzymes is very important to the DNA digestion process. The
restriction enzymes used were Oral, EcoRV, PvuII, and Stul and are detailed in Figure 5.
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Figure 5: Restriction Enzyme. Displays restriction enzyme cuts as predicted on two
different FeLV templates (Accession Numbers NC_00 1940. I and AB060732. I). The red
portions stretch from approximately 6500 bp to 7300 bp and represent slight differences in the
templates that could cause changes in the predicted digest.
DNA templates were digested with restriction enzymes Dral, EcoRV, PvuII, and Stul
according to the Clontech Genome Walker manual. After the protocol was complete,
reactions were incubated overnight at 37°C.
Purification of Digested DNA
A Clontech NucleoSpin@ Gel and PCR Clean-up Kit was used to purifY the digested
DNA samples according to the provided manuals. Once clean-up was complete, purified
DNA samples were placed into new microcentrifuge tubes and stored at -200C.
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Ligation of DNA to Adapters
A Clontech Genome Walker kit was used to ligate adapters to purified DNA digests.
4.8 ilL of purified DNA samples were ligated following manufacture reagents and
instructions. Samples were then stored at -20°C.
Polymerase Chain Reactions
Primary PCR wells for a reaction were prepared with DNA from ligated samples and
components from Clontech Advantage 2 PCR Enzyme System according to the user manual.
If bands were present in the gel electrophoresis image of primary PCR products, a secondary
PCR reaction was employed. Secondary PCR wells for a reaction were prepared with
samples from the primary PCR and components from Clontech Advantage 2 PCR Enzyme
System according to the user manual. Recations were run under the same thermocycling
conditions.
Initial conditions for PCR involved four steps. The first step was one cycle at 95°C for
10 minutes. The second step was forty cycles of 95°C for 30 seconds, followed by 60°C for
30 seconds, and noc for 80 seconds. Step three was one cycle at noc for 7 minutes and
step four was one cycle at 40°C for 10 minutes.
Upon optimization of technique for our samples, Touch Down-PCR conditions were
employed. This involved five steps. The first step was one cycle at 95°C for 60 seconds.
The second step was seven cycles of 95°C for 30 seconds followed by noc for 3 minutes.
The third step was thirty-two cycles of 95°C for 30 seconds followed by 67°C for 3 minutes.
Step four had one cycle at 67°C for 7 minutes. The final step was a 4°C hold until removed
and stored at -80°C. The conditions of the TD-PCR arc depicted in Figure 6.
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Step 1: 1x Step 2: 7x Step 3: 32x Step 4: 1x 00
Figure 6: PCR Cycling Conditions. The Touchdown PCR program consists of an initial "hot
start" at 95°C to activate the taq polymerase, 7 cycles with an annealing temperature of noc,
32 cycles with an annealing temperature of 67°C, and a final extension at 67°C. The high
initial annealing temperature allows more selective binding of the FeLV primers to the
genomic DNA, minimizing mispriming (non-specific annealing to the template).
Gel Electrophoresis
Gel Electrophoresis was performed using a 1.2% agarose gel. About 3 mL of Gel Red
intercalating nucleic acid stain was inserted in the dissolved gel mixture before setting in the
gel tray. Gels were run at 90 mV for approximately an hour. Time varied depending on the
degree of separation of the bands. Gels were read on a Bio-Rad gel imaging system.
DNA Extraction from Gels
Bands of interest were directly extracted from secondary PCR gels. A UV lamp was
used to make bands visible so that they could be cut out. Once bands were cut out from a gel
they were weighed and placed in a column. 200 ilL of buffer NTI was added to the column
for each 100 mg of gel. NucleoSpin Gel extraction instructions were followed to clean up the
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samples. Once clean-up was complete, concentrations of extractions were measured using
Nanodrop instrument.
Cloning and Transformation
A PureLink@Quiek Plasmid Miniprep Kit was used to isolate plasmid DNA and
plasmid DNA samples were stored at -20°C. LB agar plates containing ampieilin (100
microliters/mL) or eanamycin (50 microliters/mL) were prepped. For cloning a Tapa TA
cloning kit for sequencing from Life Technologies was used. 4 ilL plasmid DNA samples, I
ilL of salt solution, and I ilL of Tapa vector were mixed and incubated at room temperature.
Previously prepared DH5 a-competent cells were used for transformation.
Extraction of Colonies
Colonies were extracted using PureLink Quick Plasmid DNA Miniprep kits and
following manufacturer instructions. Concentrations of extractions were then measured using
Nanodrop instrument and were prepared for sequencing.
Sequencing
Samples were prepared for sequencing by diluting to 50 ng/llL. Samples with
measured concentrations lower than 50 ng!~lLwere sent to sequencing without dilution.
Samples were submitted for standard Sanger sequencing at the University of Michigan Core
Sequencing Lab.
Results and Discussion
The presence of FeLV-B was confirmed following PCR using primers RB53 and
RB 17. The PCR reactions were performed under the initial conditions, not TD-PCR. This
yielded an amplicon of 857 bp. Figure 7 shows the agarose gel image obtained.
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Figure 7: peR Gel Electrophoresis Image. A 1.2% agarose gel image confirmed the
presence ofFeL V-B in genomic DNA extracted from blood samples of FeLV-positive cats.
These samples were extracted from the gel, cleaned up, and sent to the University of
Michigan Core DNA Sequencing Lab for sequencing. A sequencing chromatogram was
obtained for the amplicon from cat 10 and was confirmed to match FeLV-B proviral
sequences. Figure 8 shows this chromatogram.
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Figure 8: Sequencing Chromatogram. This is the sequencing chromatogram for the
amplicon of FeLV-B obtained from Cat 10 blood extractions.
The chromatogram showed appropriate signal to noise ratio, little interference, and
alignment with envelope regions. While alignment with envelope regions was confirmed
some differences were observed. These differences are highlighted in Figure 9.
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Figure 9: Sequencing Chromatogram Differences. This again shows the sequencing
results for the amplicon of FeLV-B for Cat 10 (Figure 7). The sequence is shown aligned with
the envelope region ofFeL V-B (NCB! Accession Number NC_001940.l). Differences are
highlighted in the sequence, and the corresponding sections from the chromatogram are
shown. The differences are thought to be mutations.
Sequencing results shown in Figure 7, Figure 8, and Figure 9 display successful
amplification of exogenous FeLV sequences from non-infected feline blood. These results
also served as a template to design FeLV-specific primers for TD-PCR and genome walking.
PCR amplification was then performed on tissue samples using the amended touchdown-PCR
conditions. The gel imaging of primary and secondary PCR reactions using DNA extractions
from FeLV infected brain samples is shown in Figure 10.
Figure 10: Primary and Secondary peR from Brain Samples. An example of multiple
bands obtained from Primary PCR and then Secondary PCR of brain samples with restriction
enzymes Stul, Oral, Pvull-HF, and EcoRV-HF and using primer API- BIR.
These bands as well as bands from lymph samples were extracted, cloned, purified,
sequenced and are still being evaluated by our research team. A few bands returned
successful sequencing results and are detailed in Table 3.
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Table 3: Sample Sequence Information. The following table gives the conditions of
sequenced samples following cloning and extraction of plasmid DNA.
Sequence ID Cat# Sample # Tissue Type Restriction
Enzyme
2338683 23 6 Brain Pvull-HF
2338684 23 6 Brain Dral
2338679 23 2 Lymph Dral
2338669 23 4 Lymph Dral
2338680 23 .., Lymph Dral.)
2338682 23 5 Brain Pvull-HF
2338678 23 I Lymph Dral
Upon receiving sequencing data from these samples, the Clustal bioinformatics
computer program was utilized for multiple sequence alignment. The alignments of these
sequences are shown in Figure II.
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Figure 11: Clustal Multiple Sequence Alignment. This figure details the alignment of
sequences from brain and lymph samples. Sequences are continued in seven consecutive
rows with sample IDs listed on left. The only mismatches seen in the alignment are at the
beginning and end of the sequences, where the base pair assignments are less reliable.
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The sequences shown in Figure II align to one another with no mismatches which
provides confidence in our methodology and sequence results. The presence of bands in both
primary and secondary PCR and data returned from sequencing demonstrates successful
amplification of exogenous FeLV-B sequences from brain tissue, indicating that feline brain
tissue has cellular receptors which are recognized by FeLV-B. This is significant because
previous research with FeLV-C suggested that brain cells have a resistance to the virus and
that only endogenous FeLV-B sequences would be found within the central nervous
system.fJ5]
Furthermore, the research performed was successful in designing primers. Primers
were designed based on sequencing results and are in use with optimized PCR conditions
allowing our research team to move forward and sequence the entire proviral insert and
adjacent host genes.
Future Directions
Future directions include continued sequencing of the entire proviral insert and
adjacent host genes to help better understand how insertion sites relate with disease
manifestation and progression. Primer walking using optimized methodology is being
performed to determine proviral sequences in tissue samples, as well as the insertion site of
the provirus. Results of tissue samples will be compared to those of blood samples to note
any differences between the sequences. Furthermore, we plan to translate sequences to the
protein it would produce in order to detail differences in our sequences to mutations that have
been characterized in literature.
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The FeLV genome we sequenced is similar to sequences of samples collected
worldwide, with the exception some differences in a small region of the LTR. Natural
isolates of virus from small geographical regions have unique sequences in the LTR, which
are thought to lead to varied disease progression. FUIiher research will yield detailed sequence
information for a close group of cats in southeast Michigan that can be compared to the LTR
for other natural strains of FeLV, and correlated with disease progression within the group.
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Abstract
Feline Leukemia Virus (FeLV) is a transmittable RNA retrovirus that inhibits feline
immune systems and predisposes its host to infections and diseases. Much is unknown about
FeLV, including the nature and location of its insertion sites. Identifying insertion sites of the
provirus can provide information about mechanisms of tumorigenesis and identify new proto-
oncogenes. To search for insertion sites, gene-specific primers were designed and a genome
walking method was optimized for our application. Using the optimized process, blood and
tissue samples were examined for FeLV provirus. The cat from which we received samples
showed neurological symptoms before death; therefore, we hypothesized FeLV sequences would
be present in brain tissue. We also hypothesized that brain sequences and insertion sites would
differ from specific sequences found in blood and other tissue samples. Exogenous FeLV-B
sequences were successfully amplified from blood, brain and lymph tissues and no differences
were found between sequences. Exogenous sequences in the brain indicate the presence of
cellular receptors recognizable by FeLV-B. This is significant because previous research
suggested that brain cells have a resistance to the virus. Furthering knowledge of mechanisms
and locations of insertion can lead to a more complete understanding of FeLV disease
progression, ultimately leading to the development of more effective treatments, conserving the
health of domesticated and large endangered feline species.
